Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.59+0.00 (+0.29%)

Close on Nov 11, 2026Market cap $164.37MP/E –Yield –

Earnings

Humacyte's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Mar 18, 2027

Q4 FY2026 · estimated, before the open

Revenue, Q3 FY2026

$1.03M

+36.5% on a year earlier

EPS, Q3 FY2026

-$0.06

-$0.11 a year earlier

Latest guidance

Issued

Nov 10, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Humacyte's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q4 FY2026ended Dec 31, 2026	Mar 18, 2027Expected	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Nov 10, 2026before the open	$1.03M	+36.5%	-$0.06	Release
Q2 FY2026ended Jun 30, 2026	Aug 12, 2026before the open	$406.00K	+34.9%	-$0.16	Release
Q4 FY2025ended Dec 31, 2025	Mar 19, 2026before the open	–	–	–	Release
Q3 FY2025ended Sep 30, 2025	Nov 12, 2025before the open	$753.00K	–	-$0.11	Release
Q2 FY2025ended Jun 30, 2025	Aug 11, 2025before the open	$301.00K	–	-$0.24	Release
Q1 FY2025ended Mar 31, 2025	May 13, 2025before the open	–	–	$0.28	Release
Q4 FY2024ended Dec 31, 2024	Mar 28, 2025before the open	–	–	-$0.16	Release
Q3 FY2024ended Sep 30, 2024	Nov 8, 2024before the open	–	–	-$0.33	Release
Q2 FY2024ended Jun 30, 2024	Aug 13, 2024before the open	–	–	–	Release
Q1 FY2024ended Mar 31, 2024	May 10, 2024before the open	–	–	-$0.29	Release
Q4 FY2023ended Dec 31, 2023	Mar 22, 2024before the open	–	–	-$0.24	Release
Q3 FY2023ended Sep 30, 2023	Nov 9, 2023after the close	–	–	-$0.25	Release
Q2 FY2023ended Jun 30, 2023	Aug 14, 2023before the open	–	–	-$0.22	Release
Q1 FY2023ended Mar 31, 2023	May 12, 2023before the open	–	–	-$0.36	Release
Q4 FY2022ended Dec 31, 2022	Mar 24, 2023before the open	–	–	-$0.04	Release
Q3 FY2022ended Sep 30, 2022	Nov 10, 2022before the open	$31.00K	-87.1%	-$0.25	Release
Q2 FY2022ended Jun 30, 2022	Aug 12, 2022before the open	$1.30M	–	$0.35	Release
Q1 FY2022ended Mar 31, 2022	May 13, 2022before the open	$233.00K	–	-$0.19	Release
Q4 FY2021ended Dec 31, 2021	Mar 29, 2022before the open	$177.00K	–	$0.41	Release
Q3 FY2021ended Sep 30, 2021	Nov 12, 2021after the close	$241.00K	–	-$0.72	Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Humacyte's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
new hospitals	FY2026	20	–	–	Nov 10, 2026

Guidance history

Every forecast Humacyte put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Nov 10, 2026	new hospitals	FY2026	20	–

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.